Biotechnology company CytoDyn told investors on April 13 that five patients with mild-to-moderate COVID-19 symptoms were able to get off oxygen after taking its leronlimab drug, Proactive Investors reports.
Four things to know:
1. CytoDyn is enrolling patients in two COVID-19 clinical trials: one for people with mild-to-moderate symptoms and another for those in critical condition.
2. The company began treatment on 12 COVID-19 patients in its Phase 2 mild-to-moderate trial and a site has been approved for 390 patients in its Phase 2b/3 severe trial, beginning April 14.
3. So far, CytoDyn has treated more than 30 patients at four hospitals and clinics in the U.S.
4. On April 13, the company appointed Scott Kelly, MD, as CMO and head of business development. Dr. Kelly has served as director of the spine center at Atlanta-based Resurgens Orthopaedics since 2007.